Case Studies for FGI analysis

 

Case Studies for FGI analysis

  • The immune function was moderately up-regulated (center), while immunosuppressive TME was not conclusive (left). FGI predict that the sample maybe favorable for immunotherapy, with moderately up-regulated PD-L2 (PDCD1LG2) expression additionally (data not shown).
  • As for FDA approved targeted therapy drugs, one target (FGFR2) was found to be over-expression and had active network (red arrow). While K-Cell DNA-seq (WES) result showed low-level amplification of FGFR2 (data not shown). FGI predict that the sample may gain benefit from using FGFR2 inhibitor.